189 related articles for article (PubMed ID: 36432436)
1. The Synergic Effect of a Nutraceutical Supplementation Associated to a Mediterranean Hypocaloric Diet in a Population of Overweight/Obese Adults with NAFLD.
Chiurazzi M; Cacciapuoti N; Di Lauro M; Nasti G; Ceparano M; Salomone E; Guida B; Lonardo MS
Nutrients; 2022 Nov; 14(22):. PubMed ID: 36432436
[TBL] [Abstract][Full Text] [Related]
2. Association between Mediterranean Diet and Fatty Liver in Women with Overweight and Obesity.
Leone A; Bertoli S; Bedogni G; Vignati L; Pellizzari M; Battezzati A
Nutrients; 2022 Sep; 14(18):. PubMed ID: 36145146
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Zinc Supplementation on Steatosis Severity and Liver Function Enzymes in Overweight/Obese Patients with Mild to Moderate Non-alcoholic Fatty Liver Following Calorie-Restricted Diet: a Double-Blind, Randomized Placebo-Controlled Trial.
Fathi M; Alavinejad P; Haidari Z; Amani R
Biol Trace Elem Res; 2020 Oct; 197(2):394-404. PubMed ID: 32020523
[TBL] [Abstract][Full Text] [Related]
4. Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study.
Abenavoli L; Greco M; Milic N; Accattato F; Foti D; Gulletta E; Luzza F
Nutrients; 2017 Aug; 9(8):. PubMed ID: 28805669
[TBL] [Abstract][Full Text] [Related]
5. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.
Aller R; Izaola O; Gómez S; Tafur C; González G; Berroa E; Mora N; González JM; de Luis DA
Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3118-24. PubMed ID: 26367736
[TBL] [Abstract][Full Text] [Related]
6. Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.
Namkhah Z; Naeini F; Mahdi Rezayat S; Mehdi Yaseri ; Mansouri S; Javad Hosseinzadeh-Attar M
Int J Clin Pract; 2021 Nov; 75(11):e14852. PubMed ID: 34516703
[TBL] [Abstract][Full Text] [Related]
7. The Effects of a Cinchona Supplementation on Satiety, Weight Loss and Body Composition in a Population of Overweight/Obese Adults: A Controlled Randomized Study.
Chiurazzi M; De Conno B; Di Lauro M; Guida B; Nasti G; Schiano E; Stornaiuolo M; Tenore GC; Colantuoni A; Novellino E
Nutrients; 2023 Dec; 15(24):. PubMed ID: 38140292
[TBL] [Abstract][Full Text] [Related]
8. Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study.
Watanabe M; Risi R; Camajani E; Contini S; Persichetti A; Tuccinardi D; Ernesti I; Mariani S; Lubrano C; Genco A; Spera G; Gnessi L; Basciani S
Nutrients; 2020 Jul; 12(7):. PubMed ID: 32708435
[TBL] [Abstract][Full Text] [Related]
9. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH
J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343
[TBL] [Abstract][Full Text] [Related]
10. Novel nutraceutical supplements with yeast β-glucan, prebiotics, minerals, and
Nehmi-Filho V; Santamarina AB; de Freitas JA; Trarbach EB; de Oliveira DR; Palace-Berl F; de Souza E; de Miranda DA; Escamilla-Garcia A; Otoch JP; Pessoa AFM
Front Endocrinol (Lausanne); 2022; 13():1089938. PubMed ID: 36778595
[TBL] [Abstract][Full Text] [Related]
11. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
12. Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease.
Biolato M; Manca F; Marrone G; Cefalo C; Racco S; Miggiano GA; Valenza V; Gasbarrini A; Miele L; Grieco A
World J Gastroenterol; 2019 Jan; 25(4):509-520. PubMed ID: 30700946
[TBL] [Abstract][Full Text] [Related]
13. Lifestyle and silymarin: a fight against liver damage in NAFLD associated - prediabetic disease.
Colletta C; Colletta A; Placentino G
J Diabetes Metab Disord; 2020 Dec; 19(2):883-894. PubMed ID: 33520810
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
Chakrabarty M; Jha AN; Sharma DJ
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
[TBL] [Abstract][Full Text] [Related]
15. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.
Friedrich D; Marschall HU; Lammert F
BMC Gastroenterol; 2018 Jun; 18(1):76. PubMed ID: 29866129
[TBL] [Abstract][Full Text] [Related]
16. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
[TBL] [Abstract][Full Text] [Related]
17. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease.
Shao C; Ye J; Li F; Feng S; Wang W; Zhong B
Dig Liver Dis; 2019 Oct; 51(10):1392-1399. PubMed ID: 30928418
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.
Copaci I; Lupescu I; Caceaune E; Chiriac G; Ismail G
Rom J Intern Med; 2015; 53(1):54-62. PubMed ID: 26076562
[TBL] [Abstract][Full Text] [Related]
19. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Jazayeri-Tehrani SA; Yaseri M; Hosseinzadeh-Attar MJ
Trials; 2021 Nov; 22(1):801. PubMed ID: 34774104
[TBL] [Abstract][Full Text] [Related]
20. Non-Alcoholic Fatty Liver Disease is Associated with Higher Metabolic Expenditure in Overweight and Obese Subjects: A Case-Control Study.
Reddavide R; Cisternino AM; Inguaggiato R; Rotolo O; Zinzi I; Veronese N; Guerra V; Fucilli F; Di Giovanni G; Leandro G; Giannico S; Caruso MG
Nutrients; 2019 Aug; 11(8):. PubMed ID: 31394881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
